Effects of advanced glycation end products on ezrin-dependent functions in LLC-PK1 proximal tubule cells

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 609-616

  Bach, Leon A ^a,c   Gallicchio, Marisa A ^a   McRobert, E Anne ^a   Tikoo, Anjali ^a   Cooper, Mark E ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Advanced glycation end products; Diabetes; Diabetic complications; ERM proteins; Ezrin; Kidney; Nephropathy; Proximal tubule

Indexed keywords

ACTIN; ADVANCED GLYCATION END PRODUCT; CELL MEMBRANE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EZRIN; MOESIN; RADIXIN;

ANIMAL CELL; CELL ADHESION; CELL MOTILITY; CELL SHAPE; CELL STRAIN; CONFERENCE PAPER; CYTOSKELETON; DIABETES MELLITUS; DIABETIC NEPHROPATHY; KIDNEY PROXIMAL TUBULE; NONHUMAN; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

EID: 23744470202     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1338.069     Document Type: Conference Paper

References (42)

1. JERUMS, G. et al. 2003. Evolving concepts in advanced glycation, diabetic nephropathy and diabetic vascular disease. Arch. Biochem. Biophys. 419: 55-62.
2. BROWNLEE, M. 1994. Glycation and diabetic complications. Diabetes 43: 836-841.
3. THORNALLEY, P.J. et al. 2003. Quantitative screening of AGEs in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 375: 581-592.
4. BEISSWENGER, P.J. et al. 1995. Formation of immunochemical AGEs precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44: 824-829.
5. VLASSARA, H. et al. 1994. AGEs induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. USA 91: 11704-11708.
6. FORBES, J.M. et al. 2001. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44: 108-114.
7. WAUTIER, J.L. et al. 1996. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97: 238-243.
8. HAMMES, H. et al. 1991. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. USA 88: 11555-11558.
9. KIHARA, M. et al. 1991. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc. Natl. Acad. Sci. USA 88: 6107-6111.
10. RUMBLE, J.R. et al. 1997. Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J. Clin. Invest. 99: 1016-1027.
11. FORBES, J.M. et al. 2004. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53: 1813-1823.
12. BROWNLEE, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
13. GIARDINO, I., D. EDELSTEIN & M. BROWNLEE. 1994. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. J. Clin. Invest. 94: 110-117.
14. NEEPER, M. et al. 1992. Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of proteins. J. Biol. Chem. 267: 14998-15004.
15. SOULIS, T. et al. 1997. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40: 619-628.
16. LI, Y.M., A.X. TAN & H. VLASSARA. 1995. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat. Med. 1: 1057-1061.
17. LI, Y. et al. 1996. Molecular identity and distribution of advanced glycation endproducts receptors: Relationship of p60 to OST48 and p90 to 80K-H membrane proteins. Proc. Natl. Acad. Sci. USA. 93: 11047-11052.
18. OHGAMI, N. et al. 2001. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J. Biol. Chem. 276: 13348-13355.
19. YOUSSEF, S. et al. 1999. Effect of diabetes and aminoguanidine therapy on renal advanced glycation endproduct binding. Kidney Int. 55: 907-916.
20. MCROBERT, E.A. et al. 2003. The amino terminal domains of ERM proteins bind advanced glycation endproducts: an interaction that may play a role in the development of diabetic complications. J. Biol. Chem. 278: 25783-25789.
21. TSUKITA, S. & S. YONEMURA. 1999. Cortical actin organization lessons from ERM (ezrin/radixin/moesin) proteins. J. Biol. Chem. 274: 34507-34510.
22. TURUREN, O., T. WAHLSTROM & A. VAHERI. 1994. Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J. Cell Biol. 126: 1445-1453.
23. BRETSCHER, A., R. GARY & M. BERRYMAN. 1995. Soluble ezrin purified from placenta exists as stable monomers and elongated dimers with masked C-terminal ERM association domains. Biochemistry 34: 16830-16837.
24. SIMONS, P. et al. 1998. C-terminal threonine phosphorylation activates ERM proteins to link the cell's cortical bilayer to the cytoskeleton. Biochem. Biophys. Res. Commun. 253: 561-565.
25. YAO, X., A. THIBODEAU & J.G. FORTE. 1993. Ezrin-calpain 1 interactions in gastric parietal cells. Am. J. Physiol. 265: C36-C46.
26. NG, T. et al. 2001. Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. EMBO J. 20: 2723-2741.
27. 2-terminal domain inhibits the cell extension activity of the COOH-terminal domain. J. Cell Biol. 128: 1081-1093.
28. DOI, Y. et al. 1999. Normal development of mice and unimpaired cell adhesion/cell motility/actin-based cytoskeleton without compensatory up-regulation of ezrin or radixin in moesin gene knockout. J. Biol. Chem. 274: 2315-2321.
29. TAKEUCHI, K. et al. 1994. Perturbation of cell adhesion and microvilli formation by antisense oligonucleotides to ERM family members. J. Cell Biol. 125: 1371-1384.
30. KAUL, S.C. et al. 1999. Identification of a 55-kDa ezrin-related protein that induces cytoskeletal changes and localizes to the nucleolus. Exp. Cell Res. 250: 51-61.
31. AMIEVA, M.R. et al. 1999. Disruption of dynamic cell surface architecture of NIH3T3 fibroblasts by the N-terminal domains of moesin and ezrin: in vivo imaging with GFP fusion proteins. J. Cell Sci. 112: 111-125.
32. ORLANDO, R.A. et al. 2001. The glomerular epithelial cell anti-adhesion podocalyxin associates with the actin cytoskeleton through interactions with ezrin. J. Am. Soc. Nephrol. 12: 1589-1598.
33. SOMLO, S. & P. MUNDEL. 2000. Getting a foothold in nephrotic syndrome. Nat. Genet. 24: 333-335.
34. TAKEDA, T. et al. 2001. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J. Clin. Invest. 108: 289-301.
35. MIFSUD, S.A. et al. 2001. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 44: 878-882.
36. BAINS, R., P.N. FURNESS & D.R. CRITCHLEY. 1997. A quantitative immunofluorescence study of glomerular cell adhesion proteins in proteinuric states. J. Pathol. 183: 272-280.
37. CORTES, P. et al. 2000. F-actin fiber distribution in glomerular cells: structural and functional implications. Kidney Int. 58: 2452-2461.
38. ZHOU, X. et al. 1995. High glucose alters actin assembly in glomerular mesangial and epithelial cells. Lab. Invest. 73: 372-383.
39. KlM, E.K. et al. 1992. Corneal endothelial cytoskeletal changes in F-actin with aging, diabetes and after cytochalasin exposure. Am. J. Ophthalmol. 114: 329-335.
40. CREPALDI, T. et al. 1997. Ezrin is an effector of HGF-mediated migration and morphogenesis in epithelial cells. J. Cell Biol. 138: 423-434.
41. CHEN, J., J.A. COHN & L.J. MANDEL. 1995. Dephosphorylation of ezrin as an early event in renal microvillar breakdown and anoxic injury. Proc. Natl. Acad. Sci. USA 92: 7495-7499.
42. CHEN, Z. et al. 2001. Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by IL-1 alpha and EGF. Cancer 92: 3068-3075.